Time filter

Source Type

A Coruña, Spain

Grande E.,Ramon y Cajal University Hospital | Aparicio L.A.,Universitario runa
Stem Cells in Cancer: Should We Believe or Not? | Year: 2014

This volume explores the latest developments in a novel area of molecular biology and a hot topic in the field of oncology: cancer stem cells. These chapters from expert contributing authors present concepts such as the universal stem cell, new molecular pathways, new targeted agents, the different roles that cancer stem cells seem to have according to the organ they are placed in, and the future role that targeting cancer stem cells may have in the management of patients in the clinic. Exploring the latest research including new data from randomized trials, this book examines important proposals over the origin of cancer stem cells such as the possibility that cancer stem cells may arise from mutated stem cells or a fully differentiated cell that may undergo several mutations that drive it back to a stem-like state. The authors consider the role that stem cells seem to have in the onset, development and resistance to classical antitumoral treatments of cancer and discuss possible potential future treatment modalities for the management of advanced cancer patients. The question, "Are stem cells involved in cancer?" may not have a simple answer, but ongoing investigations, in-depth consideration and a broad spectrum of information can be found in this book, allowing the reader to arrive at his or her own answer. This book will appeal to researchers in the field of oncology and cancer research and biomedical scientists with an interest in stem cells. © 2014 Springer Science+Business Media Dordrecht. All rights reserved.

Del Rey M.J.,Institute Investigacion | Izquierdo E.,Institute Investigacion | Usategui A.,Institute Investigacion | Gonzalo E.,Institute Investigacion | And 3 more authors.
Arthritis Care and Research | Year: 2010

Objective: Hypoxia is a prominent feature in rheumatoid arthritis (RA) synovium. However, its contribution to the pathogenesis of RA remains unclear. We undertook this study to systematically characterize the changes in gene expression induced by hypoxia in synovial fibroblasts. Methods We used microarray expression profiling in paired normoxic and hypoxic cultures of healthy synovial fibroblasts (HSFs) and RA synovial fibroblasts (RASFs). We used Student's paired t-test with Benjamini and Hochberg multiple testing correction to determine statistical significance. Validation of microarray data was performed by quantitative real-time reverse transcription-polymerase chain reaction analysis of selected genes. Biologic pathways differentially modulated by hypoxia in RASFs or HSFs were identified using unsupervised Ingenuity Pathways Analysis. Results Hypoxia induced significant changes in the expression of a large group of genes in both HSFs and RASFs. In RASFs, we observed a lower number of hypoxia-regulated genes and partial differences in their functional categories. The number of differentially expressed genes in RASFs compared with HSFs was significantly increased by hypoxia. Multiple gene sets involved in energy metabolism, intracellular signal transduction, angiogenesis, and immune and inflammatory pathways were significantly modified, the last in both proinflammatory and antiinflammatory directions. Conclusion These data demonstrate that hypoxia induces significant changes in gene expression in HSFs and RASFs and identify differences between RASF and HSF profiles. The hypoxia-induced gene expression program in synovial fibroblasts identifies new factors and pathways relevant to understanding their contribution to the pathogenesis of chronic arthritis. Copyright © 2010 by the American College of Rheumatology.

Introduction: The assessment of quality of life in patients with head and neck cancer is dependent on many variables. Objective: The aim of this study was to evaluate the differences in quality of life among patients treated with conservative or radical surgery for laryngeal, oropharyngeal or hypopharyngeal cancer, evaluated before and at 3 and 6 months after definitive therapy. Material and method: Prospective study between November 2008 and June 2009 on 53 patients diagnosed and treated for head and neck carcinoma with surgery: partial (n = 32) and radical (n = 21). Quality of life was evaluated using the European Organization of Research and Treatment of Cancer (EORTC) general questionnaire EORTC QLQ-C30 and its specific head and neck EORTC QLQ-H&N35 before treatment, and at 3 and 6 months afterwards. Results: No significant differences were found in overall health. Patients experienced the greatest changes in functional scale. There were no changes in swallowing problems or feeling of disease, while evident phonation problems were present in both groups. Discussion and conclusions: The routine application of quality of life questionnaires in cancer patients improves information regarding how and to what extent patients feel that treatment and its sequelae modify it, making it possible to adapt rehabilitation and support programs to their real needs. This data helps in choosing between different options depending on the results, delivering improved care to patients. © 2010 Elsevier España, S.L.

Blanco-Aparicio M.,Complejo Hospitalario Universitario runa | Vazquez I.,University of Santiago de Compostela | Pita-Fernandez S.,Universitario runa | Pertega-Diaz S.,Universitario runa | Verea-Hernando H.,Complejo Hospitalario Universitario runa
Health and Quality of Life Outcomes | Year: 2013

Background: There is some evidence that quality of life measured by long disease-specific questionnaires may predict exacerbations in asthma and COPD, however brief quality of life tools, such as the Airways Questionnaire 20 (AQ20) or the Clinical COPD Questionnaire (CCQ), have not yet been evaluated as predictors of hospital exacerbations.Objectives: To determine the ability of brief specific health-related quality of life (HRQoL) questionnaires (AQ20 and CCQ) to predict emergency department visits (ED) and hospitalizations in patients with asthma and COPD, and to compare them to longer disease-specific questionnaires, such as the St Georgés Respiratory Questionnaire (SGRQ), the Chronic Respiratory Disease Questionnaire (CRQ) and the Asthma Quality of Life Questionnaire (AQLQ).Methods: We conducted a two-year prospective cohort study of 208 adult patients (108 asthma, 100 COPD). Baseline sociodemographic, clinical, functional and psychological variables were assessed. All patients completed the AQ20 and the SGRQ. COPD patients also completed the CCQ and the CRQ, while asthmatic patients completed the AQLQ. We registered all exacerbations that required ED or hospitalizations in the follow-up period. Differences between groups (zero ED visits or hospitalizations versus ≥ 1 ED visits or hospitalizations) were tested with Pearsońs X2 or Fisheŕs exact test for categorical variables, ANOVA for normally distributed continuous variables, and Mann-Whitney U test for non-normally distributed variables. Logistic regression analyses were performed to estimate the predictive ability of each HRQoL questionnaire.Results: In the first year of follow-up, the AQ20 scores predicted both ED visits (OR: 1.19; p = .004; AUC 0.723) and hospitalizations (OR: 1.21; p = .04; AUC 0.759) for asthma patients, and the CCQ emerged as independent predictor of ED visits in COPD patients (OR: 1.06; p = .036; AUC 0.651), after adjusting for sociodemographic, clinical, and psychological variables. Among the longer disease-specific questionnaires, only the AQLQ emerged as predictor of ED visits in asthma patients (OR: 0.9; p = .002; AUC 0.727). In the second year of follow-up, none of HRQoL questionnaires predicted exacerbations.Conclusions: AQ20 predicts exacerbations in asthma and CCQ predicts ED visits in COPD in the first year of follow-up. Their predictive ability is similar to or even higher than that of longer disease-specific questionnaires. © 2013 Blanco-Aparicio et al.; licensee BioMed Central Ltd.

Monserrat L.,Universitario runa | Lopez B.,Center for Applied Medical Research | Gonzalez A.,Center for Applied Medical Research | Hermida M.,Institute Investigacion Biomedica | And 5 more authors.
European Heart Journal | Year: 2011

AimsCardiotrophin-1 (CT-1) is a cytokine that induces hypertrophy in cardiomyocytes and is associated with left ventricular hypertrophy (LVH) in hypertensive patients. The objective of this study was to evaluate whether plasma CT-1 is associated with hypertrophic cardiomyopathy (HCM).Methods and resultsThe study was performed in 124 patients with HCM. All patients underwent a full clinical evaluation and an echocardiogram. Left ventricular hypertrophy was evaluated by the measurement of the maximal LV wall thickness and the Spiritos LVH score. Plasma CT-1 was measured by an enzyme-linked immunosorbent assay. Compared with controls, patients with HCM exhibited higher (P < 0.001) plasma CT-1 levels. Significant correlations were found between CT-1 and maximal LV wall thickness (r 0.284, P 0.001) and the Spiritos LVH score (r 0.287, P= 0.006) in HCM patients. In addition, the levels of CT-1 were higher (P< 0.02) in patients with severe LVH (maximal LV wall thickness <30 mm) than in patients with mild or moderate LVH (maximal LV wall thickness <30 mm).ConclusionsThese findings show that plasma CT-1 is associated with the severity of LVH in patients with HCM. Further studies are required to ascertain whether CT-1 is a diagnostic biomarker of this cardiomyopathy. © 2011 The Author.

Discover hidden collaborations